ImmunityBio (IBRX) Asset Writedowns and Impairment (2014 - 2023)

ImmunityBio (IBRX) has 4 years of Asset Writedowns and Impairment data on file, last reported at $886000.0 in Q4 2023.

• Asset Writedowns and Impairment for Q4 2023 came in at $886000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was -$9.8 million (changed N/A YoY), and the FY2023 annual result was $886000.0, up 30.1% from the prior year.
• Asset Writedowns and Impairment rose to $886000.0 in Q4 2023 per IBRX's latest filing, from -$10.7 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $10.7 million in Q3 2020 and troughed at -$10.7 million in Q4 2020.
• A 3-year average of $402500.0 and a median of $805000.0 in 2019 frame the typical range for Asset Writedowns and Impairment.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 1572.38% in 2020 and fell as far as 1572.38% in 2020.
• A 3-year view of Asset Writedowns and Impairment shows it stood at $724000.0 in 2019, then sank by 1572.38% to -$10.7 million in 2020, then soared by 108.31% to $886000.0 in 2023.
• Business Quant data shows IBRX's Asset Writedowns and Impairment at $886000.0 in Q4 2023, -$10.7 million in Q4 2020, and $10.7 million in Q3 2020.